Updated Sep 1, 2026
/Primis Financial director Allen Jones resigns, board falls to ten/Westlake Corporation (WLK) names Tommy Darby chief accounting officer at $440,000 base salary/FDHCX declares $0.0753 monthly cash dividend with September 30 payment date/Global liquidity, not Fed policy, may set crypto's September course/Michelle Obama's 'I'm good' on empty nest draws criticism from commentators/Three ETFs for a $5,000 starter portfolio in 2026/Primis Financial director Allen Jones resigns, board falls to ten/Westlake Corporation (WLK) names Tommy Darby chief accounting officer at $440,000 base salary/FDHCX declares $0.0753 monthly cash dividend with September 30 payment date/Global liquidity, not Fed policy, may set crypto's September course/Michelle Obama's 'I'm good' on empty nest draws criticism from commentators/Three ETFs for a $5,000 starter portfolio in 2026

Pomerantz LLP opens investor inquiry into Elicio Therapeutics (NASDAQ: ELTX)

An investor inquiry into claims against Elicio Therapeutics, Inc. (NASDAQ: ELTX) is underway, Pomerantz LLP disclosed

By Hannah Voss2 min read
Share